Αρχική World News No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line... World News No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Από Ogkologos - 3 Μαρτίου, 2026 431 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Lo que deben saber las personas con cáncer de mama y... 4 Ιανουαρίου, 2024 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer 27 Ιουνίου, 2025 Does Too Much Fructose Help Colorectal Cancers Grow? 29 Οκτωβρίου, 2021 Scientists developing urine and blood tests to detect brain tumours 23 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Snowboarder Kimmy Fasani Diagnosed with Breast Cancer Nine Months After Son’s... Investigating suspected prostate cancer: improving GP-patient communication Trial Should Change Care for AIDS-Related Kaposi Sarcoma in Sub-Saharan Africa Cómo solicitar Medicare cuando tiene cáncer